Gavin Strachan

@ASCO Abstract 3008: #DrlingjunZhu presented data on targeting KRAS G12D in CCA with GFH375: N=20; 75% in 3L+, ORR 40%, Med PFS 6.2 mo, OS not reached. Direction of future research in CCA @curecc @CharityAMMF @MCRCnews GI toxicities, cytopenias AEs.

@forexflowlive 🤣🤣🤣

I was half looking forward to the World Cup but you can shoot me now...

RT @curecc: Twenty years ago, a cholangiocarcinoma diagnosis often came with more questions than answers. There were few treatment options,…

Congratulation to the KRAS Pancreatic community. Coming soon to the KRAS CCA community 💚

📢 Join us for the 2026 Cleveland Cholangiocarcinoma Symposium! On June 26, 2026, leading experts, researchers, healthcare professionals, patients, and advocates will gather in Cleveland for an important day dedicated to advancing cholangiocarcinoma research, treatment, and patient care. We are honored to welcome @DrHaleyEllis as our keynote speaker. 🗓 Date: June 26, 2026 🕚 Time: 11:00 AM – 4:30 PM 📍 Location: Cleveland Clinic, Taussig Cancer Institute (Building CA) This symposium will serve as a vital platform for collaboration, education, and innovation as we work together to address the challenges of cholangiocarcinoma. ✅ Register today at curecca.link/cleveland.

@GIcancerDoc presents phase 3 #FIGHT-302 study of #pemigatinib in patients with #CCA with #FGFR2 gene fusion at #ASCO26 @ASCO @JCO_ASCO @curecc @CharityAMMF @atuvibi @VoiesBiliaires #APIC @CcaEns @PrecisionBTCnet

🟦FIGHT-302 #ASCO26 @ASCO 1L pemigatinib vs gem-cis in advanced BTC with FGFR2 rearrangement ✅1.5mo median PFS benefit 🚨Similar OS, 24.4mo (50% crossover) ⚠️Closed early due to slow accural ✅My takeaway: Patients with FGFR+ should access the drug either in 1 or 2 L Pemigatimib is an option in 1L for patients ineligible for chemo or IO #cancer #biliary #oncology #cholangiocarcinoma #MedX @OncoAlert

Pemigatinib for untreated mCCA with FGFR2 rearrangement: Phase 3 FIGHT-302 results. #ASCO26 👉4500+ pts screened! 👉ORR 47%, PFS 8.3mo 🧐Compelling efficacy, confirmative in 2L and alternative option in 1L @myesmo @ASCO

National Cancer Survivors Month Grateful to be in the company of these survivors(friends) Steven West – Dx 2015
Lisa Craine – Dx 2010
Patrick Corrigan – Dx 2006
Melinda Bachini – Dx 2009
Matt Reidy – Dx 2013 Thank you @curecc for your advocacy and for building a community

🚨 FIGHT-302 at #ASCO26 Pemigatinib vs CisGem in 1L FGFR2 rearranged BTC • PFS 8.3 vs 6.8 mo • ORR 47% vs 15% • OS 24.4 vs 25 mo 🤔 Does this change the algorithm or lack of evidence given no IO + CisGem? 😯 An option for pts who need response? @_SEOM @atuvibi @GrupoTTD

CCF Chief Medical Officer Dr. Juan Valle discusses how the #KRAS inhibitor research provides incredible hope for patients with #cholangiocarcinoma in the future. #pancreaticcancer #KRASinhibitor #daraxonrasib

Love seeing all the CCA posters from ASCO 💚

We are so grateful to Sleepy Saturday for designing a special pajama set in honor of Sydney Towle! This pajama set is on sale from June 1-15 with half the proceeds benefitting CCF's patient and research programs. Syd, a patient with cholangiocarcinoma, has raised awareness throughout her journey so far, ensuring others feel supported. We are so glad Sleepy Saturday is providing her an additional platform and support to our entire community through this fundraiser.  You can order here: sleepysaturday.com/product-page/s… Please note these pajamas are being specially made for this fundraiser and after you pre-order, you will receive them in a couple months. Thank you for your support!

CholangioConnect mentors understand the unique nature of facing a cholangiocarcinoma diagnosis because they have lived it. Mentors are patients, caregivers, and bereaved caregivers who use their experience to be active listeners, sounding boards, and steadfast supporters for their mentees. This is a free service and participants report finding comfort through having a peer understand and listen to them. Please learn more and sign up for a mentor at curecca.org/get-one-on-one…. #cholangiocarcinoma #peersupport

Our CCF Team is looking forward to connecting with advocates, clinicians, researchers, industry partners, and community members at the ASCO Annual Meeting in Chicago this weekend. If you are at the meeting, please stop by Booth #13000 and visit with team members who are ready to share information on the latest resources such as CholangioPath - our new app available in the App Store for download. Please come by and say hello! #ASCO26 #ASCO2026 #CholangioPath #CancerResearch

🩺💚 The 2026 Cleveland Cholangiocarcinoma Symposium is bringing together leading experts, researchers, healthcare professionals, patients, and advocates for an important day of collaboration, education, and progress in cholangiocarcinoma research and treatment. 📅 June 26, 2026 ⏰ 11:00 a.m. – 4:30 p.m. 📍 Cleveland Clinic – Taussig Cancer Institute 5th Floor, Room CA5-120 10201 Carnegie Ave, Cleveland, OH 🚗 Parking vouchers provided at check-in. Valet and garage parking available. 🔗 Register today at curecca.link/cleveland

🧬 Is MASLD Driving the Rise of Intrahepatic Cholangiocarcinoma (ICC)? Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a potential contributor to ICC pathogenesis, prognosis, and clinical management 🔗oaepublish.com/articles/2394-… #Cholangiocarcinoma

💬 Will metabolic disease become a major therapeutic focus in ICC? 🧬 Definitely ⚖️ Likely in selected patients 📊 More mechanistic evidence needed ❌ Viral & genetic factors remain dominant Vote & discuss 👇 @staclinds @DavidBobbitt @VivekSubbiah @YannickBuccella @zucchiatti_

I am looking forward to @ASCO's annual mtg. If you will be there, please stop by the #Cholangiocarcinoma Foundation Booth #13000. We hope to see you there! #ASCO26 #ASCO #CancerResearch #HopeInResearch

Honoring the brave men and women who made the ultimate sacrifice for our freedom. This Memorial Day, we remember and are grateful.